Postherpetic Neuralgia Clinical Trial
Official title:
Efficacy of Etoricoxib in Patients With Neuropathic Pain With and Without Peripheral Hyperalgesia - A Prove of Concept Trial
The purpose of the study is to determine the efficacy of etoricoxib on pain patients. The investigators assume that patients with neuropathic pain will have greater pain relief then patients on placebo.
Status | Terminated |
Enrollment | 9 |
Est. completion date | August 2012 |
Est. primary completion date | August 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients over 18 years with - Persistent moderate or severe pain (> 4 on NRS (1..10)) at rest (average of three daily assessments using a diary for at least two days) . - Neuropathic pain associated with a clinical and neurologically proven peripheral nerve injury, radiculopathy, postherpetic neuralgia or polyneuropathy or CRPS - One of the two following QST phenotypes at the baseline assessment: - signs of peripheral hyperalgesia (that means, pathological decreased heat pain threshold and/or pathological decreased muscle pain threshold) - without signs of peripheral hyperalgesia (no pathological decreased heat - and/or muscle pain threshold) - Patients of both gender - Signed consent form - Patients with the ability to understand and follow the instructions of the doctor Exclusion Criteria: - Excluded will be patients Parkinson's disease or a history of cerebral vascular insult or nerve injury. Excluded will be also all patients with contradictions for the use of Etoricoxib: - Hypersensitivity to the active substance or to any of the excipients. - Active peptic ulceration or active gastrointestinal (GI) bleeding. - Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetyl-salicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors. - Pregnancy and lactation - Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score =10). - Estimated renal creatinine clearance <30 ml/min. - Inflammatory bowel disease. - Congestive heart failure (NYHA II-IV). - Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled - Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease. - Intake of one of the following drugs (current or in the last 3 days) - selective-serotonin-reuptake-inhibitor - cetoconazole - rifampicin - phenytoin - carbamazepine - dexamethasone or other systemic corticoids - traditional nonsteroidal antiphlogistics - cyclooxygenase-inhibitors - immunosuppressives - TNF-a-inhibitors |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Bergmannsheil department of pain therapy | Bochum | Nordrhein-Westfalen |
Lead Sponsor | Collaborator |
---|---|
Ruhr University of Bochum |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Superior improvement of peripheral hyperalgesia at day six after initiation of Cox-2-inhibiting-medication in comparison to placebo | 12 month | No | |
Secondary | Reduction of the average on-going pain | reduction of the average on-going pain decrease of the neuropathic symptoms intensity (NPSI score) decrease of the patients global impression of change (PGIC) decrease of the frequency and cumulative 7 day dosage of rescue medication | 12 month | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546334 -
Erector Spinae Plane Block in Post-herpetic Neuralgia
|
N/A | |
Completed |
NCT01688947 -
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Terminated |
NCT01744522 -
Leech Therapy for Postherpetic Neuralgia
|
N/A | |
Completed |
NCT00566904 -
New Topical Treatment for Continued Pain After Shingles
|
Phase 1 | |
Completed |
NCT00478179 -
Study of a Bupivacaine Patch (Eladurâ„¢) to Treat Post- Herpetic Neuralgia
|
Phase 2 | |
Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
Terminated |
NCT01603394 -
Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
|
Phase 4 | |
Completed |
NCT01251211 -
Botulinum Toxin in Peripheral Neuropathic Pain
|
Phase 4 | |
Completed |
NCT01228838 -
Study of NGX-1998 for the Treatment of Postherpetic Neuralgia
|
Phase 2 | |
Completed |
NCT00612105 -
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
|
Phase 2 | |
Recruiting |
NCT04560361 -
The Analgesic Effect of Electroacupuncture on Postherpetic Neuralgia
|
N/A | |
Recruiting |
NCT05568186 -
Correlation Between Thermal Patterns of Infrared Thermal Imaging and Clinical Phenotype in Patients With Postherpetic Neuralgia
|
||
Recruiting |
NCT04664530 -
The Study on the Esketamine in the Treatment of Postherpetic Neuralgia
|
Phase 4 | |
Active, not recruiting |
NCT01508676 -
Effects of Pennsaid on Clinical Neuropathic Pain
|
N/A | |
Completed |
NCT00885586 -
Acupuncture in Herpes Zoster Neuralgia (ACUZoster)
|
Phase 4 | |
Completed |
NCT00576108 -
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00981227 -
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
|
Phase 2 | |
Completed |
NCT00238511 -
An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00007501 -
Shingles Prevention Study
|
Phase 3 | |
Completed |
NCT04594226 -
Electroacupuncture Therapy for Treating Postherpetic Neuralgia
|
N/A |